Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

The Healthcare Partnership is launched

Offers brand implementation to pharma and medical device industries

- PMLiVE

Novartis and Pfizer to collaborate on NASH combinations

Big pharma giants target nascent multi-billion market

- PMLiVE

GSK’s says depot HIV injection works over three years

The injection could rival Gilead’s single-tablet therapy

Neurodiversity, ADHD and work: Obstacles and opportunities

For ADHD awareness month this year our Associate Medical Writer, Alex Teahan, has written a piece surrounding ADHD and employment. He discusses the advantages and disadvantages of ADHD at work,...

Mednet

- PMLiVE

Budget 2018: UK life sciences sector delivers its verdict

UK Chancellor Philip Hammond delivered a budget that was broadly pro-business but contained mixed news for the life sciences industry, according to two industry bodies.The headline news of an additional...

- PMLiVE

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Both companies made same error in modelling, says NICE

- PMLiVE

US ‘unicorn’ Samumed on track with lead arthritis drug

Its injectable improved pain, joint function and patient global scores

Page & Page: PMEA finalists 2018

Page & Page have been shortlisted for the "Excellence in Marketing Established Products" award for their work in the nutrition industry.

Page & Page Health

- PMLiVE

What’s in store in the final (maybe short-lived) pre-Brexit budget?

The UK pharma and biotech sectors are hoping for measures to support investment in R&D and manufacturing when Chancellor Philip Hammond delivers the last pre-Brexit budget later today.Hammond has however...

- PMLiVE

US pricing plan slammed for imposing “foreign price controls”

Trump returns to popular theme ahead of mid-term elections

- PMLiVE

In conversation with Pfizer’s Erik Nordkamp

Pfizer’s UK managing director and newly appointed ABPI President talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe

- PMLiVE

After mixed signals, will Eisai and Biogen press on with Alzheimer’s hopeful?

Sub-study aimed at addressing doubts raises more questions

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links